How an entry gets written
Every entry follows the same structure: Mechanism, What the evidence shows, Safety & considerations, and Sources. We start from the primary literature where it's accessible — FDA labels, PubMed, clinical trial registries — and fall back to well-sourced secondary reviews only where the primary material isn't practically accessible (this comes up most with older Russian-language research on peptides like Semax and Selank).
What we won't do
We don't include dosing protocols, reconstitution instructions, or injection guidance for any compound, approved or not — that's a decision made by a prescriber for approved drugs, and there is no responsible version of that guidance for unapproved research chemicals. We also don't sell anything, link to vendors, or accept compensation from any supplier.
Living document
Every entry carries a "last reviewed" date. Evidence changes — a Phase 3 trial reads differently than a Phase 2, and a compound that's investigational today may be FDA-approved next year (or may quietly disappear from serious research entirely). We aim to revisit entries as new major evidence emerges, particularly for anything in active late-stage trials.
Limits, honestly
This is a small editorial project, not an institution. We can get things wrong, miss a paper, or fall behind on a fast-moving trial program. If you spot something outdated or inaccurate, the fastest way to get it fixed is to tell us directly — see the About page for contact details.